Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Aducanumab: Updated Phase Ib data

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Neurimmune Holding AG, Schlieren, Switzerland Product: Aducanumab (BIIB037) Business: Neurology Molecular target: Beta amyloid Description: Human recombinant anti-beta amyloid…

    Published on 7/27/2015
  • Adult stem cells: Phase II data

    Mesoblast Ltd. (ASX:MSB; Pink:MBLTY), Melbourne, Australia Product: Adult stem cells, Mesenchymal precursor cells (MPC) (JR-031, CEP-41750) Business: Renal Molecular target: Not applicable Description: Allogeneic adult …

    Published on 7/27/2015
  • Adynovate: Additional Phase II/III data

    Baxalta Inc. (NYSE:BXLT), Deerfield, Ill. Nektar Therapeutics (NASDAQ:NKTR), San Francisco, Calif. Product: Adynovate (BAX 855) Business: Hematology Molecular target: Factor VIII Description: Pegylated form of …

    Published on 7/27/2015
  • Aerosurf: Phase IIa data

    Discovery Laboratories Inc. (NASDAQ:DSCO), Warrington, Pa. Product: Aerosurf Business: Pulmonary Molecular target: NA Description: Aerosolized KL4 surfactant Indication: Treat respiratory distress syndrome (RDS) in …

    Published on 7/27/2015
  • Amyvid florbetapir: Clinical trial data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Amyvid florbetapir (18F-AV-45) (formerly Florpiramine) Business: Diagnostic Molecular target: Beta amyloid Description: Imaging agent labeled with fluorine 18 (F…

    Published on 7/27/2015
  • Benzhydrocodone/acetaminophen: Clinical trial data

    KemPharm Inc. (NASDAQ:KMPH), Coralville, Iowa Product: Benzhydrocodone/acetaminophen (KP201/APAP) (KP201) Business: Neurology Molecular target: NA Description: Abuse-deterrent formulation of benzhydrocodone, a …

    Published on 7/27/2015
  • Birinapant: Preliminary Phase IIa data

    TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Birinapant (formerly TL32711) Business: Cancer Molecular target: Inhibitor of apoptosis (IAP) Description: Small molecule peptidomimetic of diablo …

    Published on 7/27/2015
  • CCX140: Additional Phase II data

    ChemoCentryx Inc. (NASDAQ:CCXI), Mountain View, Calif. Product: CCX140 Business: Renal Molecular target: CC chemokine receptor 2 (CCR2) (CD192) Description: Inhibitor of CC chemokine receptor 2 (CCR2; CD192) Indication:…

    Published on 7/27/2015
  • CK-2127107: Phase I data

    Cytokinetics Inc. (NASDAQ:CYTK), South San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: CK-2127107 Business: Neurology Molecular target: Sarcomere Description: Fast skeletal muscle troponin…

    Published on 7/27/2015
  • Cometriq cabozantinib: Phase III data

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Product: Cometriq cabozantinib (XL184) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1); c-Met …

    Published on 7/27/2015
  • Eravacycline: Additional Phase III data

    Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH), Watertown, Mass. Product: Eravacycline (TP-434) Business: Infectious Molecular target: NA Description: Broad-spectrum fluorocycline antibiotic Indication: Treat complicated…

    Published on 7/27/2015
  • Evofosfamide: Additional Phase I/II data

    Threshold Pharmaceuticals Inc. (NASDAQ:THLD), South San Francisco, Calif. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Evofosfamide (formerly TH-302) Business: Cancer Molecular target: NA Description: Hypoxia-…

    Published on 7/27/2015
  • Fanapt iloperidone: Interim Phase III data

    Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Washington, D.C. Product: Fanapt iloperidone Business: Neurology Molecular target: Serotonin (5-HT2) receptor; Dopamine receptor Description: Serotonin (5-HT2) receptor and …

    Published on 7/27/2015
  • Flublok Quadrivalent: Phase III data

    Protein Sciences Corp., Meriden, Conn. Product: Flublok Quadrivalent Business: Infectious Molecular target: Not available Description: Quadrivalent seasonal influenza vaccine made with recombinant hemagglutinin antigens…

    Published on 7/27/2015
  • Gevokizumab: Phase III data

    Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Servier, Neuilly-sur-Seine, France Product: Gevokizumab (S 78989, XOMA 052) Business: Inflammation Molecular target: Interleukin-1 (IL-1) beta Description: Humanized IgG2 mAb …

    Published on 7/27/2015
  • Intranasal sumatriptan powder: Additional Phase IIIb data

    OptiNose Inc., Yardley, Pa. Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Product: Intranasal sumatriptan powder, OptiNose sumatriptan (AVP-825) Business: Neurology Molecular target: NA Description: Low-dose sumatriptan …

    Published on 7/27/2015
  • Irinotecan: Phase I data

    Baxalta Inc. (NYSE:BXLT), Deerfield, Ill. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), Cambridge, Mass. PharmaEngine Inc. (TPEx:4162), Taipei, Taiwan Product: Irinotecan (nal-IRI) (PEP02, MM-398) Business: Cancer …

    Published on 7/27/2015
  • ISIS-SMNRx: Additional Phase II data

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ISIS-SMNRx Business: Neurology Molecular target: Survival of motor neuron 2 centromeric (SMN2) Description: Antisense oligonucleotide that modulates …

    Published on 7/27/2015
  • IV ANAVEX 2-73: Interim Phase IIa data

    Anavex Life Sciences Corp. (OTCQX:AVXL), New York, N.Y. Product: IV ANAVEX 2-73 Business: Neurology Molecular target: Sigma-1 receptor; Muscarinic receptor Description: Aminotetrahydrofuran derivative agonist of sigma-1…

    Published on 7/27/2015
  • IV CR845: Phase II data

    Cara Therapeutics Inc. (NASDAQ:CARA), Shelton, Conn. Chong Kun Dang Pharmaceutical Corp. (KSE:001630), Seoul, South Korea Maruishi Pharmaceutical Co. Ltd., Osaka, Japan Product: IV CR845 Business: Dermatology Molecular …

    Published on 7/27/2015
  • IW-1973: Phase I data

    Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Product: IW-1973 Business: Cardiovascular Molecular target: Soluble guanylate cyclase (sGC) Description: Soluble guanylate cyclase (sGC) stimulator …

    Published on 7/27/2015
  • Latuda lurasidone: Phase III data

    Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Latuda lurasidone (SM-13496) Business: Neurology Molecular target: Dopamine D2 receptor; …

    Published on 7/27/2015
  • MDCO-216: Phase I data

    The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. Product: MDCO-216 (formerly ET-216) Business: Cardiovascular Molecular target: Cholesterol Description: Complex of dimeric recombinant apolipoprotein A-1 Milano and a …

    Published on 7/27/2015
  • Mitizax: Phase III data

    ALK-Abello A/S (CSE:ALK-B), Horsholm, Denmark Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Mitizax (House Dust Mite Allergy Immunotherapy Tablet (HDM AIT)) (MK-8237, TO-203) Business: Inflammation Molecular …

    Published on 7/27/2015
  • NPH29: Clinical trial data

    nPharmakon LLC, Piscataway, N.J. Product: NPH29 Business: Dermatology Molecular target: Cyclooxygenases (COX); Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Cyclooxygenases (COX), …

    Published on 7/27/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993